PLIVA Enters Oncology Business in Germany

PLIVA d.d.PLIVA d.d. announced that its German subsidiary AWD.pharma GmbH & Co. KG. ("AWD") has signed an agreement to acquire O.R.C.A.pharm GmbH ("ORCApharm"), a privately owned specialty pharmaceutical company focused on the oncology market in Germany. Upon closing of the transaction, AWD will pay a fixed purchase price of EUR 21m and up to an additional EUR 13m based on the achievement of profitability milestones for 2007 and 2008.

"Our acquisition of ORCApharm, a well established player in the German oncology market, provides us with a strategic platform for entering the highly lucrative oncology business in Germany and strongly supports our corporate strategy of focusing on markets with greater barriers-to-entry and thus greater value," commented Željko Čović, President of PLIVA's Management Board and COO. "The acquisition of ORCApharm and its current product portfolio further supports our commitment to the European oncology market and strengthens the foothold we have already established through our Czech subsidiary PLIVA Lachema, which focuses on the development, production and distribution of vertically integrated injectable cytostatic products. Furthermore, we are confident that we will deliver additional product synergies by expanding ORCA's portfolio to include select PLIVA and Barr products that complement oncology treatments, such as our pain and CNS franchises."

About PLIVA d.d.
PLIVA d.d. is the European generic pharmaceutical subsidiary of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company that operates in more than 30 countries. The Barr Group of companies is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients.

Established in 1921 and with headquarters in Zagreb, Croatia, PLIVA is the leading Central and Eastern European (CEE) pharmaceutical company and has a portfolio of 550+ products that compete in the key markets of Croatia, Czech Republic, Germany, Poland and Russia. PLIVA's product portfolio includes solid dose forms, injectables, creams/ointments, Over-The-Counter (OTC) products, cytostatics, and active pharmaceutical ingredients (APIs). PLIVA is also an emerging participant in the generic biopharmaceutical arena. For more information visit http://www.pliva.com

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...